Eiger BioPharma up on positive data from pediatric disorder study

Eiger Biopharmaceuticals

28/06/2021 15:56

** Shares of biopharmaceutical co  EIGR.O  rise 7.8% to
$9.35
    ** Co presents positive data from mid-stage study of its
experimental treatment, Avexitide, in patients with congenital
hyperinsulinism (HI), a pediatric disorder  urn:newsml:reuters.com:*:nPn3rWFVva
    ** HI is characterized by hypoglycemia or low blood sugar
due to excess secretion of insulin by pancreas; persistent
hypoglycemia causes neurological and developmental complications
    ** Study enrolled 13 patients who received single
incremental doses of avexitide or placebo by continuous IV
infusion
    ** Avexitide demonstrated significant reductions in glucose
infusion requirements to maintain normal glucose levels
    ** Data presented at American Diabetes Association's 81st
Scientific Session
    ** Stock down ~24% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))